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Abstract: Background & Aims:Radiofrequency thermal ablation
(RFA) is a minimally invasive technique used as standard local ther-
apy of hepatocellular carcinoma and second-line treatment for met-
astatic liver tumors. Studies in preclinical models and in patients
have shown that thermal destruction of tumor tissue can enhance
anti-tumor cellular responses, but our knowledge of its impact on
natural killer (NK) cells is still very limited.
Methods: Thirty-seven patients undergoing RFA for hepatocellular
carcinoma were studied for peripheral blood lymphocytes counts fol-
lowed by phenotypic and functional characterization of NK-cell
population.
Results: Peripheral blood lymphocytes kinetics revealed an
increased frequency and absolute number of NK-cells expressing
higher levels of activatory along with reduced levels of inhibitory
NK receptors, and increased functional NK-cell activity. A prevalent
expansion of the CD3()CD56(dim) NK subset was observed com-
pared to the CD3()CD56(bright) counterpart. Interferon-gamma
production, anti-K562 cell-cytotoxicity, and antibody-dependent
cell-cytotoxicity, appeared consistently increased in terms of both
absolute activity and killing efﬁciency at 4 weeks after RFA, as com-
pared to baseline. Interestingly, when recurrence-free survival was
assessed in two groups of patients separated according to higher vs
lower enhancement of cytotoxicity and/or interferon-gamma pro-
duction, a signiﬁcant difference was observed, thus suggesting a
potential predictive role of NK functional assays on efﬁcacy of RFA.
Conclusions:RFA can lead to stimulation of NK-cells with a more
differentiated and proactivatory phenotypic proﬁle with general
increase of functional activities. This observation may be relevantJournal of Hepatology 20
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for the Study of the Liver.Radiofrequency thermoablation (RFTA) has become a possible
standard of care treatment option for patients with early HCC
according to Barcelona Clinic Liver Cancer (BCLC). Recently, much
focus has been put on its efﬁcacy and safety in comparison to sur-
gical resection. In a recent report published in Gastroenterology
[1], Missale and colleagues describe a new potential mechanism
of action occurring in HCC patients undergoing RFTA.
Thirty-seven patients with HCC were treated with RFTA. Phe-
notype, number, and function of natural killer (NK) cells were
analyzed one week before and one and four weeks after ablative
therapy. Follow up included three monthly contrast-enhanced
ultrasound examinations and six monthly CT scans. In contrast
to CD3+, CD4+, CD8+ T cells, and CD19+ B cells, the absolute
and relative frequency of CD16+ CD56+ NK-cells increased upon
RFTA in HCC patients. Apart from an increase in expression of
the activating receptors (NKG2D, CD16, NKp44, and NKp30) as
well as a decrease in expression of the inhibitory receptor NKG2A
on NK-cells, an enhanced NK mediated cell-cytotoxicity and IFN-
c production was documented in HCC patients four weeks after
RFTA. Interestingly, RFTA also increased the capacity of anti-
body-dependent cell mediated cytotoxicity (ADCC), supporting
the idea of a new treatment modality, in which RFTA might be
combined with monoclonal antibody based therapies. Finally,
the authors present preliminary data suggesting that enhanced
NK-cell function after RFTA treatment is associated with
improved disease-free survival.
The study by Zerbini et al. touches three very relevant
areas, which have increasingly become the focus of mainly pre-
clinical investigations in HCC as well as in tumor immunology
in general.
First, this report adds on to the list of different studies demon-
strating the relevance of NK-cells in the context of HCC. Previous
work has shown that NK-cell function is already impaired in
patients with liver cirrhosis supporting the development of pro-
gression of HCC. In addition, we have recently shown that fre-
quency and function of NK-cells in HCC patients is impaired10 vol. 53 j 775–776
Fig. 1. Local ablative treatment caused by RFTA, cryoablation, TACE, and PDT
can cause different types of tumor death. Dying tumor cells lead to the release
of antigens, which are presented by heat shock protein-activated dendritic cells,
and at the same time different types of immune cells (macrophages/monocytes, T,
and NK-cells) become activated in the local environment of the dying tumor.
International Hepatologypossibly through an increase of a suppressor cell population
called myeloid derived suppressor cells [2]. Moreover, preclinical
studies suggest a potential efﬁcacy of NK-cell based immunother-
apy for the treatment of HCC.
Most importantly, this study adds to the already existing and
currently upcoming literature on the effect of tumor cell death on
tumor-speciﬁc immune responses [3]. While it was generally
believed that apoptotic tumor cell death induces anergy whereas
necrotic cells augment inﬂammation, others and we have shown
that not only necrotic tumor cell death can dampen immune
responses, but also that apoptotic tumor cell death can mount
tumor-speciﬁc immune responses in vivo [4]. In HCC, tumor
destruction can be induced through different mechanisms includ-
ing RFTA, cryoablation, photodynamic therapy, and transarterial
chemoembolization. All these ablative therapies have been
shown to have potent effects either directly or indirectly on the
adaptive as well as innate immune response. Apart from activa-
tion of NK-cell function as shown in the study by Zerbini et al.,
there is strong preclinical data demonstrating that RFTA leads
to release of tumor antigens and attracts dendritic cells into776 Journal of Hepatology 201tumor draining lymph nodes. It should be noted that others have
also reported RFTA dependent changes in the function of antigen-
presentation as well as T cell responses (Fig. 1).
Currently, it is not clear what type of ablative therapy induces
the most potent immune responses in vivo. Induction of anti-
tumor immune responses have been observed in preclinical
mouse models after RFTA, PDT, and cryotherapy [5,6]. Sporadic
remission of tumor metastasis distant from ablated tumors has
also been observed in preclinical models after RFTA treatment
of patients with prostate cancer, cryoablative therapy (colon can-
cer), and HCC patients treated with PDT and TACE. However,
more work is clearly needed in this area to understand the exact
mechanisms involved in the induction and enhancement of
immune responses upon different types of ablative therapies.
Finally, this study has addressed the interesting area of com-
bining immune based therapies with other types of HCC treat-
ment. Targeted therapies have shown limited success in
patients with advanced disease and relapse rates are still too high
in patients with potential curable disease. Therefore, new treat-
ment strategies are needed and the combination of interventional
therapies with immune based therapies represents one choice.
While progress has already been achieved in preclinical murine
studies using dendritic cell based approaches [7], there is cur-
rently one clinical trial investigating the effect of the adoptive
transfer of ex vivo activated PBMC in combination with TACE.
Well-designed future clinical trials in HCC patients will help
broaden our understanding of immunological mechanisms in
HCC, which include the interplay between the tumor and the
immune system. This will also help in identifying the effects of
non-immune based therapies on tumor-speciﬁc immune
responses as well immune suppressor mechanisms in HCC.Conﬂict of interest
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